BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.28 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call Transcript

May 30, 2020 / 12:00AM GMT
Craig West;Heng Liang
BeiGene, Ltd. - Senior Director of IR;BeiGene, Ltd. - CFO & Chief Strategy

Hello, everyone, and welcome to BeiGene's ASCO Data Review Zoom Webinar. My name is Craig West, and I'm the Head of Investor Relations here at BeiGene.

We have 2 distinguished clinician speakers with us today, Dr. Constantine Tam from the Peter MacCallum Cancer Center in Melbourne, Victoria, Australia; and Dr. Andrew Zelenetz from the Memorial Sloan Kettering Cancer Center in New York, New York. Joining us from BeiGene as presenters are John Oyler, our Chairman, Co-Founder and CEO; CFO -- excuse me, Howard Liang, CFO and Chief Strategy Officer; Eric Hedrick, Chief Adviser; Yong Ben, Chief Medical Officer of Immuno Oncology; and we will also be having Xiaobin Wu; Jane Huang; and Josh Neiman available during Q&A. After the presentations, we will take your questions. (Operator Instructions) As a reminder, today's call will be recorded.

I would now like to introduce your host for today's conference, Howard Liang. Howard, let me turn the call over to you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot